Intravacc

Intravacc is a Dutch CDMO and vaccine innovator offering integrated services from early-stage discovery to GMP manufacturing for Phase I/II trials. The company's core strength lies in its proprietary, time-tested technology platforms, including a Vero cell-based system for viral vaccines and platforms for conjugate and E. coli-expressed protein vaccines. With a legacy dating back to its predecessors, Intravacc provides partners with a de-risked, scalable path for vaccine development, supported by deep regulatory and analytical capabilities.

Proprietary platforms include: 1) A Vero cell-based platform for viral vaccines (oncolytic, live-attenuated, inactivated, vector), scalable using microcarriers in bioreactors. 2) A conjugate vaccine platform for bacterial infections and therapeutic applications. 3) An E. coli expressed protein vaccine platform.

Intravacc competes with large, full-service CDMOs (e.g., Lonza, Catalent) and other specialized vaccine/biologics CDMOs. Its differentiation lies in its deep, platform-specific vaccine expertise, historical legacy, and integrated service offering from discovery to Phase II, carving out a niche in the early-stage vaccine development space.